Wire · opportunities
FDA panel loosens restrictions for controversial peptides popular online
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
An FDA advisory panel voted to loosen restrictions on unregulated peptides like BPC-157 and TB-500, allowing compounding pharmacies to produce them despite lack of clinical human trials. Health Secretary RFK, a vocal proponent, has signalled intent to reverse Biden-era restrictions on the growing online wellness market.
This Wire brief sits within Fusion42's coverage of Digital Health, and 12 sources have reported it between 22 Jul 2026 and 31 Jul 2026.
◆ ◆ The Wire takeaway
If you're building a telehealth, supplement, or wellness platform, you now have a legal route to peptide sales that didn't exist last month. The FDA panel's vote opens compounding pharmacies as your distribution layer, and RFK's presence in government means this deregulation will likely stick.
◆ Coverage
12 sources · first reported 22 Jul 2026 · latest 31 Jul 2026
◆ Related on Wire
◆ Topics